株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のRNA干渉(RNAi)治療市場見通し

Global RNA Interference (RNAi) Therapy Market Outlook 2018

発行 KuicK Research 商品コード 302592
出版日 ページ情報 英文 300 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界のRNA干渉(RNAi)治療市場見通し Global RNA Interference (RNAi) Therapy Market Outlook 2018
出版日: 2014年03月01日 ページ情報: 英文 300 Pages
概要

RNAi技術は近年注目され、基礎研究およびドラッグデリバリーの重要な一要素となりました。過去数年でRNAi技術は学術界および産業界の双方において、遺伝子の機能特定や経路解析、標的バリデーションプロセスにおいて欠かすことのできないものとなっています。

当レポートでは、RNAi治療の概要とニーズ分析、RNAiに関する利点とドラッグデリバリーの仕組み、世界のRNA干渉(RNAi)治療市場の動向、治験パイプライン動向とともに、参入する企業の競合環境をまとめ、概略下記の構成で取り上げております。

第1章 RNA干渉(RNAi)治療のイントロダクション

  • RNAi治療のニーズ
  • RNAi技術

第2章 RNA干渉(RNAi)治療のメリット

第3章 RNA干渉(RNAi)ドラッグデリバリーの仕組み

  • 標的バリデーションにおけるRNAiの役割
  • 標的同定におけるRNAiの役割

第4章 世界のRNA干渉(RNAi)治療市場概要

  • 地域別市場
  • 継続中の治験

第5章 市場動向

  • 市場促進因子
  • 解決すべき課題
  • 将来的成長の機会

第6章 相、適応、国別パイプライン

第7章 中断・中止されたRNAiプロファイル

第8章 競合環境

  • Arrowhead Research
  • Alnylam Pharmaceuticals
  • Benitec Biopharma
  • Dicerna Pharmaceuticals
  • InteRNA Technologies
  • Isis Pharmaceuticals
  • RXi Pharmaceuticals
  • Santaris Pharma
  • Silence Therapeutics
  • Tekmira Pharmaceuticals Corporation

図表

目次

The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry.

Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts.

There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be "undruggable" by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market.

The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits.

Global RNAi Therapy Report Highlights:

  • Introduction & Need Analysis of RNAi Therapy
  • Benefits & Drug Delivery Mechanics Related to RNAi
  • RNAi Therapy Market Insight
  • Ongoing Clinical Trail/Pipeline for RNAi
  • Detailed Insight on 151 RNAi Based Drugs in Clinical Trial
  • Detailed Insight on 34 Suspended & No Development Reported RNAi Based Drugs in Clinical Trial

Global RNAi Therapy Report Findings:

  • Number of RNAi Based Drugs in Clinical Trials: 151
  • Highest RNAi Clinical Trial in Preclinical Phase
  • Oncology Dominating the RNAi Based Drugs Clinical Trial Process
  • US Dominates RNAi Market & Clinical Trial Landscape

Table of Contents

1. Introduction to RNA Interference (RNAi) Therapy

  • 1.1. Need for RNAi Therapy
  • 1.2. RNAi Technologies

2. Benefits of RNA Interference (RNAi) Therapy

3. RNA Interference (RNAi) Drug Delivery Mechanics

  • 3.1. Role of RNAi in Target Validation
  • 3.2. Role of RNAi in Target Identification

4. Global RNA Interference (RNAi) Therapy Market Overview

  • 4.1. Regional Markets
  • 4.2. Ongoing RNAi Therapy Clinical Trial

5. Global RNA Interference (RNAi) Market Dynamics

  • 5.1. Favorable Market Drivers
  • 5.2. Challenges to be Addressed
  • 5.3. Future Growth Opportunities

6. RNAi Clinical Pipeline by Phase, Indication & Country

  • 6.1. Unknown Phase
  • 6.2. Research
  • 6.3. Preclinical
  • 6.4. Phase-I
  • 6.5. Phase I/II
  • 6.6. Phase-II
  • 6.7. Phase-III

7. Suspended & Discontinued RNAi Profiles

  • 7.1. No Development Reported
  • 7.2. Discontinued
  • 7.3. Suspended

8. Competitive Landscape

  • 8.1. Arrowhead Research
  • 8.2. Alnylam Pharmaceuticals
  • 8.3. Benitec Biopharma
  • 8.4. Dicerna Pharmaceuticals
  • 8.5. InteRNA Technologies
  • 8.6. Isis Pharmaceuticals
  • 8.7. RXi Pharmaceuticals
  • 8.8. Santaris Pharma
  • 8.9. Silence Therapeutics
  • 8.10. Tekmira Pharmaceuticals Corporation

List of Figures

  • Figure 4-1: Global RNAi Therapy Market (US$ Billion), 2012-2018
  • Figure 4-2: RNAi Therapy Market by Region, 2013
  • Figure 4-3: Global RNAi Drug Clinical Pipeline by Phase (%), 2014
  • Figure 4-4: Global RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
  • Figure 4-5: Suspended & Discontinued RNAi Drug in Clinical Pipeline (%), 2014
  • Figure 4-6: Suspended & Discontinued RNAi Drug in Clinical Pipeline (Number of Drugs), 2014
  • Figure 4-7: Discontinued RNAi Drug Clinical Pipeline by Phase (%), 2014
  • Figure 4-8: Discontinued RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
  • Figure 4-9: Suspended RNAi Drug Clinical Pipeline by Phase (%), 2014
  • Figure 4-10: Suspended RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014

List of Tables

  • Table 8-1: Arrowhead Research Corporation RNAi Pipeline
  • Table 8-2: Alnylam Pharmaceuticals RNAi Pipeline
  • Table 8-3: Benitec Biopharma RNAi Pipeline
  • Table 8-4: Dicerna Pharmaceuticals RNAi Pipeline
  • Table 8-5: InteRNA Technologies RNAi Pipeline
  • Table 8-6: Isis Pharmaceuticals RNAi Pipeline
  • Table 8-7: RXi Pharmaceuticals Corporation RNAi Pipeline
  • Table 8-8: Santaris Pharma RNAi Pipeline
  • Table 8-9: Silence Therapeutics RNAi Pipeline
  • Table 8-10: Tekmira Pharmaceuticals RNAi Pipeline

Following Information For Each RNAi Drug Profile in Covered in More than 200 Tables in Report:

  • Active Indication
  • Phase of Development
  • Country/Region for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Technology Provider
  • Chemical/Biological Class
  • Administrative Route
  • Drug Class
Back to Top